Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab versus standard therapy in Japanese patients with lupus nephritis
jRCT1031210522Completed
- Sponsor
- GSK
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of belimumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (2 cohorts), sponsored by GSK. Primary endpoint: Number of participants with renal flare. Started Feb 2022; status: completed.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on jRCT1031210522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210522.